| Heart Failure (HF) |
1 |
1 |
| Obesity |
0 |
0.7 |
| Hypertension |
0 |
0.64 |
| Cardiovascular Imaging |
0 |
0.54 |
| Myocardial Infarction (MI) |
0 |
0.44 |
| Clinical Guidelines |
0 |
0.43 |
| Dyspnea |
0 |
0.43 |
| Exercise |
0 |
0.43 |
| Fatigue |
0 |
0.36 |
| Primary Care |
0 |
0.36 |
| Chronic Obstructive Pulmonary Disease |
0 |
0.3 |
| Type 2 Diabetes Mellitus |
0 |
0.3 |
| Ejection Fraction |
0 |
0.99 |
| SGLT2 Inhibitor |
0 |
0.29 |
| Cardiomyopathy |
0 |
0.24 |
| B-Type Natriuretic Peptide |
0 |
0.21 |
| Angiotensin II Receptor Blockade |
0 |
0.15 |
| Weight Management |
0 |
0.15 |
| Diuretics |
0 |
0.14 |
| Echocardiography |
0 |
0.14 |
| Heart |
0 |
0.14 |
| Receptors |
0 |
0.14 |
| Weight Loss |
0 |
0.14 |
| Pulmonary Edema |
0 |
0.12 |
| Renal Disease |
0 |
0.1 |
| Amyloidosis |
0 |
0.08 |
| Sarcoidosis |
0 |
0.08 |
| Artery |
0 |
0.07 |
| Edema |
0 |
0.07 |
| Hemochromatosis |
0 |
0.07 |
| Hypertrophic Cardiomyopathy |
0 |
0.07 |
| Kidney |
0 |
0.07 |
| Liver |
0 |
0.07 |
| Lung |
0 |
0.07 |
| Meta-Analysis |
0 |
0.07 |
| New York |
0 |
0.07 |
| Nonpharmacologic |
0 |
0.07 |
| Professional Societies |
0 |
0.07 |
| Quality of Life |
0 |
0.07 |